VIENNA, Austria and KING OF PRUSSIA, Pa., Sept. 17, 2015 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG announced today the pricing of its initial public offering of 9,000,000 American Depositary Shares (ADSs), representing 900,000 of its common shares, at a public offering price of $10.25 per ADS, before underwriting discounts.  All of the ADSs are being sold by Nabriva.  In addition, Nabriva has granted the underwriters an option for a period of 30 days to purchase up to 1,350,000 additional ADSs at the public offering price, less the underwriting discount.  Nabriva's ADSs have been approved for listing on the NASDAQ Global...